AB Science announces the successful completion of a EUR 3.2 million private placement

AB Science reports its revenues for the year 2025 and provides an update on its activities

Masitinib Sales Forecast and Market Size Analysis Report 2026-2034 with Focus on United States, Germany, France, Italy, Spain, United Kingdom, and Japan

AB Science announces that its stock continues to be covered by Maxim Group, with a target price of €4.00 per share

AB Science : Stonegate Capital Partners updates its coverage of AB Science’s stock with a target price of EUR 4.25 per share

AB Science is invited to present at the 2026 ENCALS annual meeting the survival data from masitinib clinical program in ALS

AB Science patent for masitinib in the treatment of metastatic castrate resistant prostate cancer formally granted in the United States with a protection until 2042

AB Science reports completion of the step 3 of phase 1, evaluating the combination of AB8939 with venetoclax for the treatment of refractory or relapsed AML

AB Science announces the successful completion of a EUR 2.3 million private placement

AB Science provides an update on its clinical program, suspending some non-priority clinical trials to focus on two clinical programs